Hematologics, Inc.
113 First Ave. North
Seattle, WA 98109
(206) 223-2700 or (800) 860-0934
Fax (206) 223-5550
www.hematologics.com

HLID#: E-0688 PATIENT NAME:
PATIENT ID#: DOB : SEX: M
UPIN: ORDERING PHYSICIAN:
SPECIMEN TYPE: Bone Marrow Aspirate
COLLECTION DATE: 3/17/2004 12:30 Pm RECEIPT DATE: 3/17/2004 02:35 Pm
REPORT DATE: 6/3/2004 ICD-9: 205.00 UNITS:
CLINIC ID#:
ACCOUNT:

Specimen: Bone marrow aspirate
Clinical History/Indications: A 36 year old male with a clinical history of bone marrow destruction and acute myeloid leukemia. A previous marrow aspirate had 87% leukemic myeloblasts (E-0332).

Flow Cytometric SSC/CD45 Differential: 44% lymphocytes, 0.8% monocytes, 22% myeloid cells, and 27% blasts.
Immunophenotypic Findings: Independent immunophenotypic analysis of the blast population reveals a myeloid origin with cell surface antigen expression of heterogeneous HLA-DR, CD38, CD13, CD33, and heterogeneous CD15, and lacking CD11b, CD14, CD16, and all lymphoid markers tested. CD34 is expressed on a subpopulation of the abnormal cell population.
Analysis/Conclusions: The above findings reveal an aberrant myeloblast population involving the bone marrow aspirate at 27% with an immunophenotype similar to those observed previously. Clinical, cytogenetic, and morphologic evaluation is required for comprehensive evaluation.

DW/MRL



Michael R. Loken, Ph.D., HCLD
Laboratory Director

Denise A. Wells, MD
Medical Director

This test was developed and its performance characteristics determined by HematoLogics, Inc. It has not been cleared or approved by the US Food and Drug Administration.